3例肝功能不良合并肥胖T2DM患者使用GLP-1制剂的病例分析  

Case Analysis on GLP-1 Preparation Used in 3 T2DM Patients with Hepatic Insufficiency and Obesity

作　　者：金芬 胡琪 郑涓[2] 钟雪玉 陈燕祥 Jin Fen;Hu Qi;Zheng Juan;Zhong Xueyu;Chen Yanxiang(The Seventh Hospital of Wuhan,Wuhan 430071,China;U-nion Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology)

机构地区：[1]武汉市第七医院药剂科,武汉430071 [2]华中科技大学同济医学院附属协和医院

出　　处：《中国药师》2018年第10期1823-1826,共4页China Pharmacist

摘　　要：临床药师通过对3例肝功能不良合并肥胖的2型糖尿病患者的进行药学监护,探讨临床药师在临床治疗中发挥的作用。临床药师参与药物治疗方案制定,对肝功能不良合并肥胖的2型糖尿病患者建议选用胰高糖素样肽-1受体激动药进行降糖治疗,降糖效果好;患者肝功能无明显改变。通过药学监护,可提高患者药物治疗的有效性和安全性。Clinical pharmacists actively participated in the glucose-lowering therapy for three type 2 diabetes patients with obesity and hepatic insufficiency to explore the role of clinical pharmacists in clinical treatment. Through the participation in the formulation of drug treatment by clinical pharmacists,GLP-1 preparation was used for hypoglycemic treatment,and the effect was promising. There was no significant change in the patients＇ liver function. By actively participating in the formulation of glucose-lowering therapy,clinical pharmacists can improve the effectiveness and safety of drug treatment.

关 键 词：肝功能不全 肥胖 2型糖尿病 胰高糖素样肽-1 

分 类 号：R97[医药卫生—药品]